Skip to main content
Explore URMC

menu

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

Research Question:
Does the drug prodromal help patients with Alzheimer's disease?

Basic Study Information

Purpose:
This is a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of RO7105705 in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period will be available to participants who complete the double-blind treatment period and who, in the judgment of the investigator, would potentially benefit from open-label RO7105705 treatment.

Location: University of Rochester; AD-CARE

Study Contact Information

Study Coordinator: Reference Study ID: GN39763 www.roche.com/about_roche/roche_worldwide.htm
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search